PMS experiences to be included in product monographs of two impotence medications

The Korea Food and Drug Administration said Friday post-marketing surveillance (PMS) experiences reported by patients treated with Eli Lilly’s Cialis and Dong-A Pharmaceutical’s Zydena, oral therapy for the treatment of erectile dysfunction, will be added to the ‘precaution in use’ section of the two medicines.

In the PMS studies, Cialis 5 mg tablets had been administered to 613 patients ove...